As of June 3, 2025, Jazz Pharmaceuticals PLC (JAZZ) reports a ROA (Return on Assets) of 4.66%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Jazz Pharmaceuticals PLC's ROA (Return on Assets)
Over recent years, Jazz Pharmaceuticals PLC's ROA (Return on Assets) has shown significant volatility. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | 4.66% |
| 2023-12-31 | 3.64% |
| 2022-12-31 | -2.07% |
| 2021-12-31 | -2.68% |
| 2020-12-31 | 3.65% |
This slight upward trend highlights how Jazz Pharmaceuticals PLC manages its efficiency in using assets to generate earnings over time.
Comparing Jazz Pharmaceuticals PLC's ROA (Return on Assets) to Peers
To better understand Jazz Pharmaceuticals PLC's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Jazz Pharmaceuticals PLC (JAZZ) | 4.66% |
| Corcept Therapeutics Inc (CORT) | 16.80% |
| Harmony Biosciences Holdings Inc (HRMY) | 14.51% |
| Amphastar Pharmaceuticals Inc (AMPH) | 10.11% |
| Horizon Therapeutics PLC (HZNP) | 5.72% |
| Supernus Pharmaceuticals Inc (SUPN) | 5.40% |
Compared to its competitors, Jazz Pharmaceuticals PLC's ROA (Return on Assets) is among the highest compared to peers, demonstrating superior efficiency in generating earnings from assets.